From: Nerve conduction study of the association between glycemic variability and diabetes neuropathy
All subjects | Type 1 diabetes | Type 2 diabetes | p value | |
---|---|---|---|---|
n | 40 | 13 | 27 | |
Age (year) | 64.1 ± 10.4 | 58.9 ± 14.4 | 66.7 ± 6.8 | 0.087 |
Disease duration (year) | 16.4 ± 10.4 | 17.7 ± 12.6 | 15.7 ± 9.4 | 0.58 |
Number of patients with hypoglycemia | 17 | 7 | 10 | 0.31 |
HbA1c (%) | 7.8 ± 1.4 | 8.1 ± 2.0 | 7.6 ± 1.0 | 0.37 |
BMI (kg/m2) | 23.5 ± 5.0 | 21.1 ± 3.92 | 24.7 ± 5.1 | 0.03 |
SBP (mmHg) | 134 ± 18 | 131.9 ± 20.8 | 134.9 ± 17.4 | 0.64 |
TG (mg/dL) | 146 ± 105 | 117.2 ± 95.1 | 160.1 ± 108.5 | 0.23 |
LDL (mg/dL) | 103 ± 25 | 118.6 ± 19.9 | 95.9 ± 24.0 | 0.005 |
eGFR (mL/min/1.73 m2) | 67.9 ± 19.9 | 75.0 ± 22.9 | 64.5 ± 17.7 | 0.12 |
UAE (mg/gCre) | 10.5 [6.5–28.6] | 9.6 [6.7–23.0] | 11.8 [5.4–37.3] | 0.65 |
MAGE (mg/dL) | 105 ± 41.9 | 119.6 ± 44.4 | 98.0 ± 39.5 | 0.13 |
Median CMAP amp (mV) | 14.4 ± 3.4 | 15.0 ± 4.2 | 14.2 ± 3.0 | 0.49 |
Median DL (m/s) | 3.93 ± 0.82 | 3.80 ± 0.61 | 3.99 ± 0.92 | 0.50 |
Median MCV (m/s) | 53.5 ± 3.72 | 53.0 ± 3.8 | 53.7 ± 3.7 | 0.56 |
Median F z score | 2.19 ± 1.49 | 1.77 ± 1.54 | 2.39 ± 1.45 | 0.23 |
Median wrist SNAP amp (µV) | 29.7 ± 13.9 | 33.0 ± 17.6 | 28.2 ± 11.8 | 0.31 |
Median SCV (m/s) | 47.0 ± 10.7 | 48.5 ± 7.1 | 46.3 ± 12.1 | 0.54 |
Tibial CMAP amp (mV) | 18.8 ± 7.1 | 20.6 ± 6.8 | 17.9 ± 7.3 | 0.26 |
Tibial MCV (m/s) | 42.5 ± 3.71 | 43.5 ± 3.8 | 42.0 ± 3.6 | 0.21 |
Tibial F z score | 2.53 ± 1.72 | 2.10 ± 1.32 | 2.73 ± 1.87 | 0.28 |
Sural SNAP amp (µV) | 14.0 ± 8.6 | 17.0 ± 11.0 | 12.6 ± 7.3 | 0.20 |
Sural SCV (m/s) | 46.6 ± 4.7 | 44.9 ± 5.3 | 47.4 ± 4.2 | 0.11 |
Medial plantar CNAP amp (µV) | 6.14 ± 6.28 | 7.28 ± 7.74 | 5.58 ± 5.53 | 0.43 |
Medial plantar NCV (m/s) | 48.4 ± 6.2 | 46.8 ± 5.4 | 49.2 ± 6.5 | 0.26 |